Select Page

PHASE II SBIR Funding Awarded to Montana Molecular

by | Apr 9, 2014

$1.1 million investment from the National Institutes of Health advances next generation tools for drug discovery in living cells. Montana Molecular, a privately-held company developing next generation tools for drug discovery in living cells, has been awarded a Phase...

DAG sensor and μ-opioid receptor desensitization

by | Apr 9, 2014

DAG sensor and μ-opioid receptor desensitization Early adopters of Montana Molecular’s DAG sensor at The Vollum Institute published new results in the British Journal of Pharmacology.  This study made good use of our Upward DAG sensor for diacylglycerol to...

DAG sensor illuminates TRPC6 Regulation

by | Apr 9, 2014

  Montana Molecular’s DAG sensor helped unravel the molecular mechanisms of TRPC6 cation channel activity which could lead to new treatments for TRPC6-associated diseases that affect cardiovascular and kidney dysfunction such as vasospasm and...

Wondering about BacMam in your favorite cell type?

by | Mar 20, 2014

BacMam technology is evolving and transduction efficiencies have improved substantially since many of these pioneering papers were published.  This body of work provides a summary of what has been accomplished and a starting point for assay optimization in your cell...

Biotek and Montana Molecular Collaborate

by | Mar 17, 2014

Montana Molecular’s assays are ideal for measuring GPCR activity on Biotek’s fluorescence plate readers!  In fact, we screen and optimize all of our fluorescent assays in-house on our Biotek Synergy MX.  We were curious about the new Biotek Cytation 3...

GEN article highlights GPCR assays from Montana Molecular

by | Jan 9, 2014

  Wondering what new cell based assays are available for screening in primary cells?  Need to detect ligand bias?  Wishing you could measure more than one second messenger with an easy multiplex assay?  Tired of multistep lytic assays for cAMP? Please check out,...